187 related articles for article (PubMed ID: 34152087)
41. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
42. AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting.
Maggi E; Montagna C
Mutat Res; 2015 Dec; 782():44-51. PubMed ID: 26554403
[TBL] [Abstract][Full Text] [Related]
43. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
44. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
45. Functional genomics for personalized cancer therapy.
Tyner JW
Sci Transl Med; 2014 Jul; 6(243):243fs26. PubMed ID: 24990879
[TBL] [Abstract][Full Text] [Related]
46. Translating genomic profiling to gastrointestinal cancer treatment.
Harada K; Mizrak Kaya D; Shimodaira Y; Song S; Baba H; Ajani JA
Future Oncol; 2017 Apr; 13(10):919-934. PubMed ID: 28067073
[TBL] [Abstract][Full Text] [Related]
47. Genomics and bioinformatics as pillars of precision medicine in oncology.
Canzoneri R; Lacunza E; Abba MC
Medicina (B Aires); 2019; 79(Spec 6/1):587-592. PubMed ID: 31864231
[TBL] [Abstract][Full Text] [Related]
48. Targeting the underlying causes of undernutrition. Cost-effectiveness of a multifactorial personalized intervention in community-dwelling older adults: A randomized controlled trial.
van der Pols-Vijlbrief R; Wijnhoven HAH; Bosmans JE; Twisk JWR; Visser M
Clin Nutr; 2017 Dec; 36(6):1498-1508. PubMed ID: 27836308
[TBL] [Abstract][Full Text] [Related]
49. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
50. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
51. Translating genomics for precision cancer medicine.
Roychowdhury S; Chinnaiyan AM
Annu Rev Genomics Hum Genet; 2014; 15():395-415. PubMed ID: 25184532
[TBL] [Abstract][Full Text] [Related]
52. Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing.
Rodriguez H; Pennington SR
Cell; 2018 Apr; 173(3):535-539. PubMed ID: 29677503
[TBL] [Abstract][Full Text] [Related]
53. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Rodon J; Soria JC; Berger R; Miller WH; Rubin E; Kugel A; Tsimberidou A; Saintigny P; Ackerstein A; Braña I; Loriot Y; Afshar M; Miller V; Wunder F; Bresson C; Martini JF; Raynaud J; Mendelsohn J; Batist G; Onn A; Tabernero J; Schilsky RL; Lazar V; Lee JJ; Kurzrock R
Nat Med; 2019 May; 25(5):751-758. PubMed ID: 31011205
[TBL] [Abstract][Full Text] [Related]
54. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
[TBL] [Abstract][Full Text] [Related]
55. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.
Nakamura Y; Fujisawa T; Taniguchi H; Bando H; Okamoto W; Tsuchihara K; Yoshino T; Ohtsu A
Cancer Sci; 2021 Nov; 112(11):4425-4432. PubMed ID: 34510657
[TBL] [Abstract][Full Text] [Related]
56. Establishment and implementation of Cancer Genomic Medicine in Japan.
Mukai Y; Ueno H
Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
[TBL] [Abstract][Full Text] [Related]
57. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
58. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
